The EUROACTION PLUS trial measured the effectiveness of a nurse-led preventive cardiology programme (EUROAC-TION) offering intensive smoking cessation PLUS optional varenicline for persistent high CVD risk smokers to reduce overall cardiovascular risk compared with usual care (UC) in general practice (GP).
Introduction
Smoking is a major independent contributor to total and cardiovascular mortality and morbidity. 1 -3 The EUROASPIRE surveys of preventive care showed that half of smokers with coronary disease and nearly 90% of smokers at high cardiovascular risk continue to smoke. 4, 5 Even though these persistent high-risk smokers are usually advised to stop, only a minority is prescribed pharmacological support or referred to smoking cessation services. However, they not only require professional and pharmacological support for smoking cessation but a comprehensive approach to lifestyle and risk factor management as well. 6, 7 A meta-analysis of comprehensive cardiac rehabilitation trials 8 showed a highly significant effect for smoking cessation in patients following an acute cardiac event (pooled OR: 0.63; 95% CI: 0.50-0.83, P ¼ 0.0008) with a reduction in total mortality. In a meta-analysis of multifactorial primary prevention trials, 9 there was also a reduction in smoking cessation (pooled OR: 0.81; 95% CI: 0.70-0.94) but little change in other risk factors and therefore no impact on total or CVD mortality. The EUROACTION trial 10, 11 demonstrated that a nurse-led multidisciplinary preventive cardiology programme for coronary patients and high-risk individuals could achieve healthier lifestyles and improved risk factor management compared with usual care (UC). However, there was less success with smoking cessation apart from some relapse prevention in coronary patients. There were very few successful new quit attempts among coronary patients and especially for individuals at high CVD risk in general practice (GP) who, despite more quit attempts (53%) in intervention compared with UC (31%), had similar abstinence rates at 1 year. Although pharmacotherapy was recommended, it was only used to a limited extent. Behavioural counselling without the support of pharmacotherapy has lower abstinence rates 12 when compared with nicotine replacement therapy (NRT) 13 or varenicline, 14 which are safe and effective in patients with coronary disease. 15, 16 EUROACTION PLUS is the first study to evaluate whether a novel, comprehensive, nurse-led, preventive cardiology programme, including intensive smoking cessation counselling and optional varenicline in persistent high CVD risk smokers, can achieve greater smoking abstinence rates while, at the same time, reducing overall cardiovascular risk compared with UC in GP.
Methods Study design and population
A multi-centre parallel group randomized controlled trial (RCT) was conducted in 20 GP across Italy, Spain, the Netherlands, and the UK. Patients were randomized individually within practices to participate in the EUROACTION intervention programme (EA+) or to be monitored for UC. The study design is shown in Figure 1 . The trial started in October 2009 and was completed in July 2011. Persistent smokers (men and women) with vascular disease or at high cardiovascular risk were identified from the practice registers ( Figure 2) .
Written informed consent was obtained from all patients and their participating partners. Clinical Trial Application approval was obtained from the Medicines and Health Care Products Regulatory Association in the UK and through EudraCT in the Netherlands, Spain, and Italy. Local ethics approval was also obtained in each country.
At the consenting interview (CI) persistent high-risk smokers who were willing to make a quit attempt were eligible for the study (Figure 2 ) because it would be inefficient to conduct a RCT of persistent high-risk smokers where most are not prepared to make a quit attempt. In patients on no treatment for BP, lipids, or diabetes, total CVD risk was estimated using Heartscore (http://www.heartscore.org/Pages/welcome. aspx, 12 February 2014, date last accessed). Written consent was obtained and patients randomized to either EA+ or to UC using an Access database programme. Patients randomized to EA+ were invited with their partner to attend a baseline assessment of lifestyle, risk factors, and drug treatment. Patients randomized to UC did not have a baseline assessment and were advised to see their GP, or other smoking cessation services, to try to quit smoking. All eligible patients and partners in EA+ were invited for a repeat assessment at 16 weeks. Those in UC were invited for an assessment 16 weeks after their recruitment to the study. For all patients not attending the final clinic visit, primary outcome was established by postal questionnaire, a telephone call, or a home visit.
Training of nurses and GPs
The nurses and GPs were centrally trained by a multidisciplinary team including a specialist nurse, dietician, physiotherapist, cardiologist, and behavioural specialist from Imperial College London. Training in smoking cessation was provided by the Tobacco Dependence Research Unit at the Royal London Hospital led by Prof. Peter Hajek. A Health Professional Manual was provided for all the nurses and GPs.
Assessment and outcome measures
Seven day point prevalence of abstinence, as reported by the patient, was chosen as the primary outcome, validated with a breath carbon monoxide level of ,10 p.p.m., because it is a well-established abstinence measure in smoking cessation research which compares well with other measures. 17 In this population of smokers who were highly nicotine dependent at baseline, reporting abstinence at the time of the final assessment was likely to be reliable especially when backed up with a negative breath carbon monoxide measurement. It would be difficult for those who had not quit to refrain from smoking over a 12 h period, the abstinence time required for a breath carbon monoxide measurement to register as negative. Whether or not the patient or partner were smoking at 16 weeks, all quit attempts since randomization were recorded. Secondary outcomes and their measurement are shown in Table 1 . The Food Habit Questionnaire was used in the original EUROACTION study. 18 The mean intake of cardio-protective foods were calculated to determine whether the European dietary guidelines were met 6 ( Table 1) . The Mediterranean Diet Score is derived from a validated questionnaire 19 and a score of 9 or more represents good adherence. A seven day physical activity recall (7D-PAR) questionnaire 20 was used to determine achievement of the physical activity goal ( Table 1) . The motion sensor device 21 was worn over 7 consecutive days at baseline (EA+ only) and at 16 weeks (EA+ and UC). Self-reported physical activity was further validated by the Chester step test (CST). 22 Blood pressure was measured twice using the Omron M6 automatic sphygmomanometer. If there was a difference of 10 mmHg or more in either systolic or diastolic blood pressure between the two measurements, a third measurement was taken. Patients and partners also reported their management history for weight, BP, lipids, and diabetes and prescriptions of cardio-protective drug therapies were recorded.
The EUROACTION PLUS programme
The nurses were centrally trained to use the baseline assessment in the EA+ arm to develop behavioural and therapeutic strategies addressing lifestyle and risk factor management according to the needs of each individual and family. 26, 27 Patients and partners were also provided with a personal record card for self-monitoring, together with an educational family support pack. Figure 3 shows the structure of the nurse-led programme.
Patients randomized to EA+ set a quit date either at randomization, or at initial assessment, but no later than 1 month following this assessment. At this point, a 12-week treatment plan for optional varenicline or NRT was discussed and commenced at the patient's request. The use of optional varenicline was intentional. This was not to be a trial of varenicline vs. placebo, but rather a trial of a preventive cardiology programme which included smoking cessation support through a behavioural intervention and pharmacological support with varenicline if required. The original EUROACTION trial protocol specified a behavioural intervention for smoking cessation coupled with pharmacotherapy as determined by local prescribing practice. In the event, cardiologists and GPs were not able to follow the protocol and very few patients received these pharmacotherapies often because of the prohibitive cost of these treatments.
Partners who were smokers were also encouraged and supported to stop smoking. Nicotine replacement therapy was available according to local prescribing policy, but varenicline was provided free of charge. Once the patient or partner stopped smoking, the nurse provided regular support and encouragement to prevent and manage relapses and any problems with pharmacotherapy.
The aim of the dietary intervention was to achieve a healthy family diet (see Table 1 ). Given that smoking cessation is associated with weight gain, 28, 29 the aim was to maintain weight rather than to achieve weight loss in overweight individuals attempting to stop smoking. The aim of the physical activity intervention was to help families to achieve the physical activity goal ( Table 1) . A pedometer was used to motivate and encourage self-monitoring. In addition, dietary and physical activity advice also took account of weight, and specific management of BP, lipids, and diabetes. The nurses monitored all these risk factors and managed patients and partners to goal (Table 1) , with prescribing support from the practice GPs.
Laboratory analyses
Total cholesterol, HDL-cholesterol, triglycerides, and glucose were measured on fasting blood samples analysed by each local laboratory at baseline (EA+ only) and at 16 weeks (EA+ and UC).
Statistical methods
Assuming a 10% smoking cessation rate in UC at 16 weeks, demonstration of a doubling of this rate in EA+ required analysis of 397 patients per arm at 16 weeks to detect a difference with 90% power or 317 patients per arm with 80% power at the 0.01 significance levels. A drop-out rate of 25% was expected in each arm (i.e. of those randomized Descriptive statistics were used to report risk factor prevalence and drug therapies in EA+ and UC. Logistic regression tested for differences in the prevalence of primary and secondary outcomes between both arms. The model was adjusted for country, sex, age, and diagnostic group (vascular or high-risk patient). Odds ratios were calculated together with 95% confidence intervals. Statistical significance was evaluated according to the Wald ×2 statistic. Given the skewed distribution of some variables, the Mann-Whitney U test was used to compare continuous distributions. Changes in these distributions from baseline to 16-week assessments in the EA+ arm were approximately normally distributed and therefore tested statistically using the paired t-test.
The statistical analysis for the primary outcome is based on intentionto-treat of all patients attending the 16-week assessment, regardless of their efforts to stop smoking. All drop-outs in whom there were no data on smoking status at 16 weeks were treated as continuing smokers in this analysis. All statistical analyses were performed using the SAS software (The SAS system. Release 9.1.3, Cary, NC, USA: SAS Institute, Inc.).
Results
A total of 696 patients (137 vascular and 559 high-risk patients) were randomized after informed consent by the end of recruitment on 31 March 2011: 350 patients to EA+ and 346 patients to UC (Figure 4) . One hundred and thirteen partners were also recruited. Sixteen week follow-up for the primary outcome was completed on 31 July 2011. There were no differences at baseline between patients randomized to EA+ or to UC (see Table 2 ). In the EA+ patient population, the mean number of years of exposure to tobacco was 39.7 (SD 10.1), and the mean number of cigarettes smoked per day was 19.6 (SD 8.9). No comparable data were collected in UC at baseline.
The primary outcome was established in 342 patients (97.7%) in EA+ and 341 patients (98.6%) in UC (see Figure 4) . There was insufficient information in 13 patients (8 EA+ and 5 UC) and they were considered to be smokers in the intention-to-treat analysis. A higher proportion of patients in EA+ had quit smoking at 16 weeks (51.2%) compared with UC (18.8%, OR: 4.52, 95% CI: 3.20-6.39). This difference in abstinence rates was seen for men and women, younger, and older patients, those with and without vascular disease and in each country ( Figure 5) . Furthermore, assuming those without breath CO validation were smokers, the results still remained highly statistically significant with 51.7% achieving the primary outcome in EA+ compared with 21.4% in UC (OR: 3.94, 95% CI: 2.83-5.48).
While prolonged abstinence was not a pre-defined outcome for the trial, Hughes et al. 30 recommend that, for short-term follow-up trials, it should be possible to determine prolonged abstinence of 4 weeks or more from the dataset. In fact, 98% of patients in EA+ and 83% in UC who had achieved the primary outcome at 16 weeks had achieved prolonged abstinence of 4 weeks or more.
In those patients who were randomized to the intervention arm and had fully participated in the EA+ programme, the quit rate was 62.4% compared with 14.7% in those who participated but did not complete, and 21.6% in those who did not participate. One-half of patients achieved good adherence to the Mediterranean diet in EA+ compared with a third in UC, with increased fish consumption and reduction in alcohol (see Table 3 ). Twice as many patients in EA+ reported achieving the European guideline of ≥30 min of moderate intensity physical activity at least five times per week compared with UC. This was reflected in improved fitness with more EA+ patients achieving the ideal METsmax on the CST in EA+ compared with UC. One-third in EA+ compared with a quarter in UC achieved the BP goal. There was a difference in body mass index (BMI) in favour of UC with nearly one-third in UC achieving an ideal BMI compared with a quarter in EA+. There were no differences in lipid or diabetes management nor in the use of cardio-protective drug therapies between the two study arms.
Health-related quality of life (HRQoL) improved with nearly one-half of patients scoring ≥75 on the EQ-VAS in EA+ compared with a third in UC. There were no differences in anxiety and depression scores between EA+ and UC. Additional results for secondary outcomes are also shown in Table 3 . Tables showing differences between EA+ and UC in mean distributions of secondary outcome measures, and changes in outcomes between baseline and 16 weeks in patients randomized to EA+ are available in Supplementary material online, Tables S1 and 2.
Cardiovascular events were reported in six study subjects overall, three in UC (one patient who died and two partners) and three in EA+ (all patients, one died). Varenicline use in the three UC participants was unknown. In the EA+ arm, one of the patients had used varenicline. In the other two patients varenicline use was unknown as they had dropped out of the study. 
Effectiveness of a preventive cardiology programme

Discussion
The EUROACTION PLUS programme is the first evaluation of a nurse-led intervention for persistent high-risk smokers which aimed to achieve smoking cessation and, at the same time, reduce total cardiovascular risk.
The programme increased by four-fold the odds of being abstinent at 16 weeks compared with UC in these persistent smokers. As importantly, these high-risk patients with vascular disease or at high risk of developing CVD also improved their dietary habits, increased physical activity levels and had better blood pressure control and all of this was associated with an improvement in HRQoL. This study is unique in achieving both more effective smoking cessation and, at the same time, an overall reduction in CVD risk in this high-risk population.
By comparison with the original EUROACTION trial, these results are much more impressive for smoking cessation. However, there are two important differences between EUROACTION and EUROACTION PLUS. Firstly, in EUROACTION PLUS, only patients who were willing to make a quit attempt were included, which is the policy of most smoking cessation programmes, whereas in EURO-ACTION all smokers were included. Secondly, in EUROACTION PLUS, varenicline was available free to all intervention patients and partners if they chose to use it. In fact 91% did so. Although pharmacotherapy was recommended in the original EUROACTION protocol, local prescribing policies and cost limited its use. Varenicline is a nicotinic acetyl choline receptor partial agonist which has proved efficacy in smoking cessation. 14, 15 A recent systematic review and meta-analysis of 22 independent trials and .9000 individuals 31 concluded that the risk of cardiovascular events associated with varenicline is insignificant, contrary to a previous review by Singh et al.
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The strength of the more recent review was the use of four summary statistics (Mantel-Haenszel versions of risk difference, relative risk, and odds ratio and Peto odds ratio) to obtain a more complete picture of the potential risks and consequently reached a more Figure 4 Consort flow chart.
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balanced conclusion. There were no reported cardiovascular events attributable to varenicline in our trial. In addition to smoking cessation, the EA+ programme also successfully achieved a healthier diet characterized by a higher Mediterranean diet score. An increase of two points on the Mediterranean diet score is associated with a 9% reduction in total mortality. 33 Although the programme was also successful in promoting physical activity and improving fitness with a doubling of patients at goal, objectively quantified by the CST in comparison with UC, the proportion at goal was still low at 16%. The pedometer still classified these patients overall as 'low active'. 34 However, compared with the general adult population, 35 smokers are reported to be even less physically active, 36 and especially at older ages. 37 The increase in fitness in our programme may be responsible, in part, for the reported improvement in HRQoL, especially the ability to carry out daily living activities.
Weight gain is considered inevitable when people stop smoking. While there was a mean weight gain of 1.63 kg (+1.27 to +2.00) for all patients at 16 weeks, one-quarter either gained no weight or actually lost weight. In this latter group, 42% had stopped smoking. By comparison, in an analysis of 62 studies of untreated quitters, 29 weight gain at 3-6 months was between 2.85 and 4.23 kg. Quitters are reported to gain 7 kg more than smokers over an 8-year period. 28 So the dietary and physical activity changes made by EA+ patients may have limited the extent of weight gain overall, with some gaining no weight or losing weight. This confirms the beneficial effects of addressing lifestyle as a whole when helping patients to stop smoking. Despite the overall weight gain in the EA+ group more patients achieved the BP goal without any difference in antihypertensive drug use between EA+ and UC. The same observation was made in the first EUROACTION trial where BP was more successfully controlled in the intervention arm despite similar use of antihypertensive medications in comparison with UC. The lifestyle changes achieved in the EA+ programme with an improvement in the Mediterranean diet and increased physical activity levels will have contributed to improved blood pressure control.
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Study limitations and implications for clinical practice
With 342 patients in EA+ and 341 in UC with smoking information, the power to detect a difference for the primary outcome was 80% at the 0.01 significance level and 90% at the 0.05 level. A minimum of 6 months prolonged abstinence is recommended as the measure for evaluating smoking cessation trials. 43 We were only able to evaluate the primary and secondary outcomes at the end of our 16 weeks nurse-led programme and whether abstinence from tobacco and the healthier lifestyle and risk factor control achieved are sustained to 1 year remains an open question. One-year follow-up studies with varenicline have reported relapse in up to half of the patients who stopped smoking in the first 12 weeks, but the difference in continuous abstinence remained statistically significant by comparison with placebo at 1 year. 14, 15 We used 7-day point prevalence as the primary outcome and according to a recent systematic review, both point prevalence and prolonged abstinence measures are comparable. 44 In addition, self-reported smoking status at the final assessment in our study was validated with a biochemical measure (breath CO). Despite the relatively short half-life of CO in the body (6 h), it is adequate for validating smoking self-report in a population of dependent regular smokers 45 who would find it difficult to refrain from smoking for a 12 h period. We know that 91% of patients opted to use varenicline in the EA+ arm, but we do not report on its use in UC. However, to the extent that varenicline was used in UC would only under-estimate the true difference in smoking cessation between the two arms. Usual care in this context included advice by the nurse to stop smoking and automatic referral to local smoking cessation services. Such referral is not routine in all persistent high-risk smokers seen in clinical practice.
In patients who agreed to participate in this trial, the option of using free varenicline was an incentive, and may limit the applicability of these results to everyday clinical practice, especially in countries where the cost of varenicline is met by the patient. In the UK, the cost is met by Effectiveness of a preventive cardiology programme the health service where the National Institute for Clinical Excellence has declared that varenicline is a cost-effective use of NHS resources. Another limitation to consider may be that only patients who were highly motivated to quit smoking were recruited. In fact, this is not a limitation, because it would be inefficient to conduct an RCT of persistent high-risk smokers where most are not prepared to make a quit attempt. In addition, the primary endpoint measured at 16 weeks does not tell us whether these abstinence rates will be sustained out to 1 year. It is likely there will be some recidivism because in all trials of smoking cessation, relapse occurs over the longer term. However, the importance of this trial is that it shows abstinence rates in the short term and, as importantly, improvements in diet and physical activity levels together with better risk factor control, thus a reduction in total cardiovascular risk.
Conclusion
In all trials of smoking cessation, the traditional objective has been to evaluate the efficacy of a specific intervention in relation to smoking abstinence alone. However, this is the first study to evaluate the effectiveness of a nurse-led preventive cardiology programme focused on persistent high-risk smokers with the object of achieving smoking abstinence and a reduction in total CVD risk. We demonstrated impressive smoking abstinence over 16 weeks with our behavioural intervention, including optional use of varenicline, and simultaneouly a reduction in overall cardiovascular risk. This was achieved through healthier diets and increased physical activity levels together with improved blood pressure control without any increase in use of antihypertensive medications. As in all smoking cessation studies, the smokers had to be willing to make a quit attempt and so our results are applicable to such patients seen in every day practice.
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